CoreRx Adds Xcelodose® Precision Powder Micro-dosing System to its Product Development Capabilities

CoreRx Adds Xcelodose® Precision Powder Micro-dosing System to its Product Development Capabilities


Tampa, FL. CoreRx, an integrated contract development and manufacturing organization supporting the international pharmaceutical and biotechnology industries, has further enhanced its offering by adding an Xcelodose® precision powder micro-dosing system to its Product Development capabilities in response to client requirements for preclinical and early phase clinical GMP supply. The Xcelodose® decreases processing time and API use - generating significant cost savings to clients.

For simple formulations of API or powder-in-capsule, the Xcelodose® system can significantly reduce processing time and API usage resulting in cost savings when compared to hand-filling options

"CoreRx is continually assessing and investing in solutions to accelerate the manufacturing of our client's clinical supplies, while ensuring quality at all times," said Mark Licarde, CoreRx's VP of Manufacturing. Licarde added: "While CoreRx has always offered API in capsule, we now see examples of some clients maintaining this approach through to phase 2 studies in an attempt to compress their overall development timelines, requiring significant quantities of capsules for which an automated solution is best. CoreRx is the only CRO in the world with a full set of Xcelodose® change parts all the way down to size 9"

The Xcelodose® system, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or API directly into capsules with a high level of accuracy. The Xcelodose® system can dispense amounts as low as 100 micrograms and up to 100 milligrams and beyond, into capsules from size 00 to size 9. Dosing directly into capsules can reduce the amount of API required. Additionally, the unit minimizes overall development time by simplifying analytical and stability protocols.

About CoreRx, Inc.

CoreRxTM focuses on supporting and streamlining the drug development process for biotechnology and pharmaceutical innovators by offering services such as pre-formulation/formulation development, analytical development, clinical manufacturing and validation engineering. We have a proven track record and extensive expertise providing comprehensive drug development services to biotechnology and pharmaceutical companies worldwide.

CoreRx, Inc. is a CGMP-compliant contract development and manufacturing facility. From its inception in 2006, CoreRx has been dedicated to solving scientific problems and providing expert pharmaceutical services to businesses required to meet the growing demand of pharmaceutical companies.

CoreRx Inc. (www.CoreRxPharma.com), headquartered in Tampa, FL, provides quality pharmaceutical formulation development, clinical trial material (Phase I, II and III) and commercial manufacturing, and analytical development/validation services to the pharmaceutical industry.

For more information, visit their website at www.corerxpharma.com, follow us on Twitter (http://twitter.com/#!/corerx), or call (813) 514-9399

 

 

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.